Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS)☆☆,★
Keywords
Cited by (0)
We thank the Arthritis Research UK for their support of Childhood Arthritis prospective Study: Arthritis Research UK grant number 20542.
This report includes independent research supported by the National Institute for Health Research Biomedical Research Unit Funding Scheme. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Y.I. is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and Arthritis Research UK Grant 20164.
- ☆☆
R.D.—none, R.C.—none, H.E.F.—Pfizer, Abbvie, Sobi, Roche, Chugai Educational & Travel Bursaries (Honoraria), E.M.B.—none, S.E.A.C.—none, J.E.D.—AbbVie travel expenses, Y.I.—none, L.R.W.—none, W.T.—none, and K.L.H.—Abbvie & Pfizer Inc. (Honoraria).
- ★
The Childhood Arthritis Prospective Study (CAPS) is funded by a research grant to the University of Manchester, United Kingdom from Arthritis Research UK, United Kingdom (Grant no. 20542). This research is also supported by the National Institute for Health, United Kingdom Research Biomedical Research Unit Funding Scheme.
- 1
W.T. and K.L.H. contributed equally to this study.